A global, proof-of-concept phase II trial of HMPL-523 in rheumatoid arthritis
Phase of Trial: Phase II
Latest Information Update: 12 Mar 2018
At a glance
- Drugs HMPL 523 (Primary)
- Indications Rheumatoid arthritis
- Focus Proof of concept; Therapeutic Use
- 12 Mar 2018 According to a Chi-Med media release, the company has submitted investigational new drug (IND) applications to US FDA to start a trial in immunology in late 2018 or early 2019.
- 02 Aug 2016 According to a Chi-Med media release, company expects to initiate this study in 2017.
- 05 Nov 2015 New trial record